Indian Contract Drug Manufacturers Benefit From Global Outsourcing, Supply-Chain Diversification, Biologics and Peptide Demand; Divi’s Laboratories Remains the Top Pick

Indian contract development and manufacturing organisation (CDMO) companies have emerged as some of the strongest performers within the pharmaceutical sector, supported by rising global outsourcing, supply-chain diversification and increasing demand for complex therapies.

The broader pharma and healthcare indices have gained around 20 per cent over the past six months, but listed CDMO players have significantly outperformed their sectoral peers. The top five listed companies deriving at least 40 per cent of their revenue from CDMO operations have delivered an average return of more than 60 per cent during the period.

Laurus Labs has been one of the biggest gainers, delivering a return of around 90 per cent.

The strong market performance reflects growing investor confidence in India's ability to capture a larger share of the global pharmaceutical manufacturing and outsourcing opportunity.

Global Pharma Outsourcing Strengthens the CDMO Opportunity

One of the biggest structural drivers for Indian CDMOs is the increasing willingness of global pharmaceutical and biotechnology companies to outsource manufacturing and development activities.

Pharma companies are looking to optimise their supply chains, reduce manufacturing costs and diversify production locations. India has emerged as an attractive destination because of its manufacturing capabilities, regulatory experience, skilled workforce and relatively competitive costs.

The trend is particularly relevant as global drugmakers reassess their dependence on concentrated manufacturing bases.

For Indian CDMOs, this creates opportunities to win new contracts, expand existing relationships and participate in the development and commercial manufacturing of complex medicines.

Supply-Chain Diversification Could Accelerate Growth

The global push to diversify pharmaceutical supply chains is emerging as another major catalyst.

Developments involving Chinese CDMO companies and growing geopolitical scrutiny of pharmaceutical supply chains could encourage US and European drugmakers to explore alternative manufacturing partners.

The inclusion of WuXi AppTec on the Pentagon's Section 1260H list and developments surrounding the BIOSECURE Act have added momentum to the supply-chain diversification narrative.

India stands to benefit because its CDMO companies combine manufacturing capabilities with established quality and regulatory standards.

For domestic companies, the opportunity extends beyond simple cost arbitrage. Global customers are increasingly looking for reliable partners capable of handling complex chemistry, specialised manufacturing and stringent quality requirements.

CDMO Market Could Expand Sevenfold by 2035

The long-term opportunity remains substantial.

India's CDMO industry currently generates an estimated $3-3.5 billion in revenue, representing only around 2-3 per cent of the global CDMO market, which is estimated at approximately $140-145 billion.

The Indian segment is projected to expand nearly sevenfold to around $22-25 billion by 2035.

If the industry achieves even a portion of this projected expansion, leading Indian CDMOs could have a significant runway for revenue and capacity growth over the next decade.

The opportunity is also attracting increasing investment in manufacturing facilities, research capabilities and specialised production infrastructure.

Biologics and Peptides Offer New Growth Engines

The next phase of CDMO growth is expected to be driven increasingly by complex and high-value therapies.

Biologics funding continues to rise, while the pipeline of biosimilar opportunities is expanding. Demand for peptides is another major growth driver.

These products generally require specialised manufacturing capabilities, creating opportunities for companies with the necessary technology, regulatory expertise and production infrastructure.

For Indian CDMOs, moving towards higher-complexity products can also improve the quality of revenue and potentially support stronger margins compared with more commoditised pharmaceutical manufacturing.

GLP-1 Drugs Boost Peptide Outsourcing

The rapid growth of GLP-1-based weight-loss and diabetes medicines has strengthened the investment case for peptide manufacturing.

Novo Nordisk, which historically manufactured complex peptide-based active pharmaceutical ingredients internally, has increasingly turned to external CDMO partners as demand for these medicines has surged.

The shift demonstrates how rapidly growing drug categories can create capacity constraints for large pharmaceutical companies and open opportunities for specialised manufacturing partners.

Indian CDMOs with peptide capabilities could therefore benefit from increased requests for proposals, feasibility studies and potential long-term commercial contracts.

Strong Q1 FY27 Performance Supports Outlook

The CDMO industry delivered another quarter of double-digit year-on-year revenue growth in Q1 FY27, according to India Ratings and Research.

While certain companies experienced temporary challenges related to customer destocking and product attrition, the broader demand environment remained healthy.

India Ratings expects the industry's growth momentum to continue through FY27, supported by robust enquiry pipelines from global innovators, improving capacity utilisation and ongoing capacity expansion.

This suggests that the sector's growth is increasingly moving from an investment-led phase towards a period in which newly commissioned facilities can begin contributing meaningfully to revenue.

Capacity Utilisation Could Improve Operating Leverage

Several Indian CDMO companies have invested heavily in expanding manufacturing capacity.

As these facilities move towards higher utilisation, companies can benefit from operating leverage, allowing fixed costs to be spread across larger production volumes.

This could provide additional support to operating margins and earnings growth.

The next stage of the industry's performance will therefore depend not only on winning new contracts but also on successfully commercialising existing investments and ramping up newly commissioned capacity.

Execution will become increasingly important as companies move from capacity creation to revenue generation.

Divi's Laboratories Remains the Preferred Pick

Divi's Laboratories continues to be the preferred company in the Indian CDMO space for several brokerages, including Macquarie and JP Morgan.

The company is recognised for its strong margins, established relationships with global pharmaceutical companies and capabilities across complex pharmaceutical ingredients.

Brokerage views also remain constructive on the company's exposure to peptide manufacturing.

The increasing demand for GLP-1 therapies and the shift towards outsourcing complex peptide-based ingredients provide a potential long-term growth opportunity for Divi's Laboratories.

However, the company's strong share-price performance has also resulted in a premium valuation, making future earnings execution increasingly important.

Laurus Labs Delivers Strong Returns

Laurus Labs has been another standout performer in the CDMO segment.

The stock has delivered approximately 90 per cent returns over the past six months, making it one of the strongest performers among listed CDMO-focused companies.

The company's growth prospects are being supported by increasing global outsourcing, capacity expansion and investments in differentiated technology platforms.

Way2Wealth Brokers has an accumulate rating on Laurus Labs, citing these factors as key drivers for the company's longer-term prospects.

With the stock trading close to its 52-week high, investors will increasingly focus on whether earnings growth can justify the sharp re-rating.

Sai Life Sciences Also Benefits From Outsourcing Trend

Sai Life Sciences is another company expected to benefit from increasing global outsourcing and expanding demand for specialised pharmaceutical development and manufacturing.

Its differentiated technology capabilities and capacity expansion provide a platform for future growth.

Brokerage expectations remain positive as global pharmaceutical companies increasingly look for partners capable of handling complex development and manufacturing requirements.

The ability to convert its project pipeline into commercial contracts will remain an important monitorable.

Syngene Offers a More Stable Profile

Syngene International continues to occupy a relatively stable position within India's contract research and manufacturing ecosystem.

The company benefits from long-standing relationships with global pharmaceutical and biotechnology customers and has exposure to research, development and manufacturing services.

However, its valuation is also considered relatively rich after the sector's strong rally.

For investors, the stock therefore represents a balance between business stability and valuation risk.

Piramal Pharma and Akums at Earlier Stages of Margin Improvement

Piramal Pharma and Akums Drugs and Pharmaceuticals are viewed as companies that are at comparatively earlier stages of margin improvement.

For these businesses, increasing utilisation, improving product mix and operating leverage could support earnings growth over the coming periods.

The potential for margin expansion provides an additional investment angle, although execution risks remain higher compared with more established CDMO leaders.

Valuations Become the Key Risk

The strong rally in CDMO stocks has significantly improved investor expectations, but it has also made valuations a key risk.

The top players are trading at an average valuation of around 66 times FY27 price-to-earnings, according to the report.

Such valuations already reflect a substantial portion of the expected growth.

This means that even if the industry's long-term fundamentals remain strong, any delay in contract wins, capacity ramp-up, margin expansion or earnings delivery could result in increased volatility.

For investors entering the sector after the sharp rally, the margin of safety is therefore considerably lower than it was before the re-rating.

Execution Will Determine the Next Phase

The industry's next growth phase is likely to be less about announcing capacity investments and more about converting those investments into revenue and profits.

Companies will need to demonstrate strong customer acquisition, capacity utilisation, product commercialisation and margin expansion.

The ability to develop long-term relationships with global innovators will also be critical because recurring contracts can provide greater revenue visibility and reduce dependence on individual products.

Companies with differentiated capabilities in complex molecules, peptides and biologics could command a premium as the market increasingly rewards specialised manufacturing.

What Investors Should Watch

Investors tracking the CDMO segment should monitor several factors closely.

New contract wins and the size of the enquiry pipeline will provide an indication of future revenue visibility. Capacity utilisation will determine whether recent capital expenditure translates into operating leverage.

The pace of global outsourcing, particularly from US and European pharmaceutical companies, will remain another key indicator.

Investors should also track developments around GLP-1 drugs, peptide manufacturing, biologics and biosimilars.

Finally, valuations need to remain a central consideration. Strong fundamentals can support premium valuations, but the higher the expectations embedded in share prices, the greater the impact of any earnings disappointment.

Market Outlook

The Indian CDMO industry continues to have a strong structural growth story, supported by global pharmaceutical outsourcing, supply-chain diversification, increasing demand for complex therapies and India's cost and manufacturing advantages.

The sector's potential expansion from an estimated $3-3.5 billion market today to around $22-25 billion by 2035 highlights the scale of the opportunity. Biologics, biosimilars and peptide-based therapies, particularly the rapidly expanding GLP-1 drug market, could provide additional high-value growth avenues.

Divi's Laboratories remains a preferred name among brokerages, while Laurus Labs and Sai Life Sciences offer exposure to capacity expansion and global outsourcing trends. Syngene provides a relatively stable profile, while Piramal Pharma and Akums could benefit from margin improvement.

However, after a sharp rally, valuations have become the primary risk. With leading CDMO companies trading at elevated earnings multiples, further share-price outperformance will increasingly depend on execution rather than simply sector optimism.

For investors, the CDMO story remains attractive for the long term, but stock selection and valuation discipline are likely to become more important as the sector enters its next phase of growth.